Since CD7 is not only widely expressed on T-ALL cells, but also on the surface of almost 90%-96% of normal T cells, the possibility of CAR-T cell cannibalism should be considered when CD7 is used as a therapeutic target (16).In conjunction with advancements in gene editing technology (e.g., CD7 knockout strategies), CD7 protein blockers, over 70 clinical trials targeting CD7 with CAR-T cells have been initiated. The gene discussed is CD7; the disease is acute lymphoblastic leukemia.